# John Harthorne

> John Harthorne is a funding round investor at Two Lanterns Venture Capital backing Health Care. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Two Lanterns Venture Capital](https://shizune.co/investors/profile/two-lanterns-venture-partners)
- Location: Boston, United States
- Total investments: 13
- Last investment: Apr 2021
- Lead investor: 23%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jharthorne
- X (Twitter): https://twitter.com/jharthorne
- Website: http://www.masschallenge.org/blog
- Facebook: http://www.facebook.com/masschallenge

John Harthorne is a funding round investor at Two Lanterns Venture Capital in Boston focused on Health Care and Apps. John Harthorne is the current Founder and Managing Director of Two Lanterns Venture Capital. John Harthorne previously founded MassChallenge, the world's largest non-profit startup accelerator. He attended MIT Sloan School of Management.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 31% |
| Apps | 2 | 15% |
| Software | 2 | 15% |
| Information Technology | 2 | 15% |
| Art | 1 | 8% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 12 | 92% |
| Pre-Seed | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 7 | 54% |
| United States | 4 | 31% |
| France | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Because | $1.3T is spent globally each year to drive traffic to ecommerce websites. Only 3% convert. That’s because most sites don’t know who you are. Because is a CRO & Personalization platform for Shopify - powered by Klaviyo dataWe help connect all the data merchants have in their tech stack across Shopify, Klaviyo, Yotpo, Loyalty Lion, Recharge,Octane, and more to create a dynamic website experience. Brands like Tom Brady’s TB12, Hello Kitty, Echelon, Duke Cannon, The Adventure Challenge, and more use Because to increase conversion by 23%+ | $650K | Pre-Seed | Apr 01, 2021 |  |
| Meetcaregivers | MeetCaregivers is on a mission to bring high-quality in-home care, additional services, products, and technology tools for all seniors’ care needs. Making it easier for seniors to access all the resources they need to age healthy and happily at home. |  |  | Apr 13, 2015 |  |
| Droplette | Droplette is their patent-pending transdermal delivery system for delivery of drugs up to 60% larger than current treatments deep into skin over large surface areas. Their unique device is painless, contact free, portable and generates no disposables. It is designed to deliver antibiotics for serious ulcers and skin infections, reducing risksecondary complications or antibiotic resistance. Future applications include localized delivery of chemotherapeutics for skin cancer and drugs for anti-aging. |  |  | Oct 29, 2014 |  |
| re:3D | re:3D reduces production complexity by providing affordable, industrial 3D printers that transform big ideas into tangible realities. With a build volume of eight cubic feet and robust construction, Gigabot can print objects 30x larger than competing desktop models. Up until now, personal 3D printing has been limited to toys and trinkets, whilethe Gigabot will bring your biggest dreams to life. re:3D's customer base comprises an esteemed group of designers, small business owners, manufacturers, educators, prototypists, and hobbyists in over 30 countries around the globe.Currently, re:3D is scaling manufacturing operations, and exploring alternate materials and feedstocks with global leaders in material and life sciences. |  |  |  |  |
| Versantis | Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, iscurrently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis. | $117K |  |  |  |
| DariX | Darix makes augmented reality applications for professionals. |  |  |  |  |
| HomePad | The application homePad Pro is made for the professional users that want to have a complete tool for managing property inspections.Available in the AppSoreHomePad is the first simple and intuitive application available on the Appstore allowing you to establish an inspection report for the outgoing / incoming tenants.The paper supportsused currently to document property inspections are particularly constraining and require significant storage space. HomePad is the first application for iPad that guides you simply and professionally through the procedure. No training is required!No documents to prepare. Begin with a new inspection or from an existing one, complete the necessary information and start the inspection. Creating new room details and checking any damage takes only a few minutes using photos and keywords! Meter reading? Key inventory? No problem, homePad has already thought it out for you! Complete the inventory using handwritten electronic signatures, generate the PDF and send it simultaneously to all parties and store it in their collaborative platform. |  |  |  |  |
| Intento | Intento develops a digital health device solution to help people recover motor function after stroke. Its solution is based on functional electrical stimulation and does not require any prior knowledge on electrode placement or involve complicated steps to configure the system, as opposed to other solutions on the market. Intento's device iscomposed of a tablet application meant to be used by therapists in conjunction with a device for patient-use. |  |  |  |  |
| Gait Up | Gait Up is a spin-off of the University Hospital of Lausanne (CHUV) and the Swiss Institute of Technology of Lausanne (EPFL), funded in 2013. Gait Up benefits from 15 years of scientific experience in the field of movement analysis and measurements, and is now providing innovative products for objective evaluation of health and performance, basedon wearable sensor technology. They are already trusted by 50+ customers in academics, clinics, and industry in Europe, Canada, US and Asia. |  |  |  |  |
| Fastree3D | Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973). |  |  |  |  |

10 of 13 investments shown.

## Co-investors
- [LaunchPad Venture](https://shizune.co/investors/profile/launchpad-venture-group) — VC Fund, 1 deal together

## About Two Lanterns Venture Capital

VC Fund · Newton, United States

Two Lanterns Venture Capital offers Pre-Seed and Seed investments in high-impact software startups in the U.S. and Israel.

1 contacts available at Two Lanterns Venture Capital.

| Name | Title | Profile |
| --- | --- | --- |
| John Harthorne | Founder and Managing Director | https://shizune.co/investors/profile/john-harthorne |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does John Harthorne invest in?

John Harthorne invests primarily in Health Care, Apps and Software startups, most often at Funding Round and Pre-Seed stage. Most of the 13 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did John Harthorne last invest?

The most recent investment recorded for John Harthorne closed in Apr 2021. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co